Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Citi
Cipla
AstraZeneca
Boehringer Ingelheim
Moodys
McKinsey
McKesson
Cerilliant

Generated: July 20, 2018

DrugPatentWatch Database Preview

EOVIST Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Eovist patents expire, and when can generic versions of Eovist launch?

Eovist is a drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-three patent family members in twenty-four countries.

The generic ingredient in EOVIST is gadoxetate disodium. One supplier is listed for this compound. Additional details are available on the gadoxetate disodium profile page.
Summary for EOVIST
International Patents:33
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 2
Clinical Trials: 11
Formulation / Manufacturing:see details
DailyMed Link:EOVIST at DailyMed
Drug patent expirations by year for EOVIST
Generic Entry Opportunity Date for EOVIST
Generic Entry Date for EOVIST*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage::
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for EOVIST

US Patents and Regulatory Information for EOVIST

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare EOVIST gadoxetate disodium SOLUTION;INTRAVENOUS 022090-001 Jul 3, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Hlthcare EOVIST gadoxetate disodium SOLUTION;INTRAVENOUS 022090-002 Feb 4, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Hlthcare EOVIST gadoxetate disodium SOLUTION;INTRAVENOUS 022090-001 Jul 3, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Hlthcare EOVIST gadoxetate disodium SOLUTION;INTRAVENOUS 022090-002 Feb 4, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for EOVIST

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,695,739 Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production ➤ Try a Free Trial
5,798,092 Derivatized DTPA complexes pharmaceutical agents containing these compounds, their use, and processes for their production ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for EOVIST

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2005 Austria ➤ Try a Free Trial PRODUCT NAME: GADOXETSAEURE DINATRIUM; NAT. REGISTRATION NO/DATE: 1-25757, 1-25758 20050302; FIRST REGISTRATION: SE 18929, 18930 20040326
0182 Netherlands ➤ Try a Free Trial 300182, 20100627, EXPIRES: 20150626
00182 Netherlands ➤ Try a Free Trial PRODUCT: GADOXETINEZUUR, DESGEWENST IN DE VORM VAN EEN ZOUT, IN HET BIJZONDER HET NATRIUMZOUT. FIRST AUTHORIZATION NO/DATE: 1829 AND 18930, 20040326 (SE); NATIONAL AUTHORIZATION NO/DATE: RVG 31393 AND 31394, 20050113
0405704/01 Switzerland ➤ Try a Free Trial FORMER OWNER: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Federal Trade Commission
UBS
Covington
US Army
McKinsey
AstraZeneca
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.